Title :

Natural history of salivary gland secretory carcinoma: A REFCOR study.

Author(s) :

Magana, Marie [Auteur]
CHU Tenon [AP-HP]
Vergez, Sebastien [Auteur]
Pôle IUCT [CHU Toulouse]
Verillaud, Benjamin [Auteur]
Hôpital Lariboisière-Fernand-Widal [APHP]
Garrel, Renaud [Auteur]
CHU Montpellier = Montpellier University Hospital
Evrard, Diane [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Mouawad, François [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
de Gabory, Ludovic [Auteur]
CHU de Bordeaux Pellegrin [Bordeaux]
Fakhry, Nicolas [Auteur]
Aix Marseille Université [AMU]
Jegoux, Franck [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Malard, Olivier [Auteur]
Regenerative Medicine and Skeleton [RMeS]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Bach, Christine [Auteur]
Philouze, Pierre [Auteur]
Hôpital de la Croix-Rousse [CHU - HCL]
Aubry, Karine [Auteur]
Université de Limoges [UNILIM]
Mauvais, Olivier [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Moya Plana, Antoine [Auteur]
Institut Gustave Roussy [IGR]
Marie, Jean Paul [Auteur]
CHU Rouen
Baujat, Bertrand [Auteur]
CHU Tenon [AP-HP]
Atallah, Sarah [Auteur]
CHU Tenon [AP-HP]

Journal title :

Surgical Oncology

Pages :

102159

Publisher :

Elsevier

Publication date :

2024-12

ISSN :

0960-7404

English keyword(s) :

Histopathology
REFCOR
Salivary gland cancers
Salivary secretory carcinoma
Survival analysis

HAL domain(s) :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie

English abstract : [en]

Background and objectivesSalivary gland Secretory Carcinoma (SC), characterized by Skalova in 2010 is a rare tumor studied within the REFCOR (French Network of experts on Rare Head and Neck Cancers). We conducted a prospective ...
Show more >Background and objectivesSalivary gland Secretory Carcinoma (SC), characterized by Skalova in 2010 is a rare tumor studied within the REFCOR (French Network of experts on Rare Head and Neck Cancers). We conducted a prospective multicentric cohort study of 108 SC cases in the REFCOR database up to July 2021, analyzing diagnostic, therapeutic, and survival data.MethodsData was collected prospectively from diagnosis to the last update. Each patient had two histological readings including one by a REFCORpath pathologist, and all cases underwent molecular testing to confirm diagnosis. Statistical analyses were performed using R software.ResultsMRI was not contributive to malignancy diagnosis. After 2 histological readings, 79 % of patients were diagnosed, with 21 % requiring molecular testing to confirm diagnosis. Surgical treatment typically involved tumor excision and lymph node dissection. The tumor exhibited low lymph node involvement, with 95 % of patients being cN0, and no nodal metastases post-dissection. Five-year overall survival and recurrence-free survival were 91.4 % {95 % CI (0.84–1)} and 89 % {95 % CI (0.81; 0.98)} respectively, indicating a favorable prognosis.ConclusionsSC is a rare and newly recognized tumor, with generally favorable outcomes. Our cohort, among the largest to date, provides valuable insights. Future research should refine treatment guidelines.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL